These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 30271138)

  • 1. Main trends of immune effects triggered by nanomedicines in preclinical studies.
    Halamoda-Kenzaoui B; Bremer-Hoffmann S
    Int J Nanomedicine; 2018; 13():5419-5431. PubMed ID: 30271138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mapping of the available standards against the regulatory needs for nanomedicines.
    Halamoda-Kenzaoui B; Holzwarth U; Roebben G; Bogni A; Bremer-Hoffmann S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 Jan; 11(1):e1531. PubMed ID: 29923692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
    Patel P; Shah J
    Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements.
    Giannakou C; Park MV; de Jong WH; van Loveren H; Vandebriel RJ; Geertsma RE
    Int J Nanomedicine; 2016; 11():2935-52. PubMed ID: 27382281
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of the blood compatibility of nanomedicines: A trend analysis of in vitro and in vivo studies.
    Urbán P; Liptrott NJ; Bremer S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1546. PubMed ID: 30556649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roadmap and strategy for overcoming infusion reactions to nanomedicines.
    Szebeni J; Simberg D; González-Fernández Á; Barenholz Y; Dobrovolskaia MA
    Nat Nanotechnol; 2018 Dec; 13(12):1100-1108. PubMed ID: 30348955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunophenotyping: Analytical approaches and role in preclinical development of nanomedicines.
    Newton HS; Dobrovolskaia MA
    Adv Drug Deliv Rev; 2022 Jun; 185():114281. PubMed ID: 35405297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
    Fadeel B; Garcia-Bennett AE
    Adv Drug Deliv Rev; 2010 Mar; 62(3):362-74. PubMed ID: 19900497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
    Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
    Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanomedical engineering: shaping future nanomedicines.
    Luo D; Carter KA; Lovell JF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical hazard evaluation strategy for nanomedicines.
    Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
    Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical immunotoxicity studies of nanotechnology-formulated drugs: Challenges, considerations and strategy.
    Dobrovolskaia MA
    J Control Release; 2015 Dec; 220(Pt B):571-83. PubMed ID: 26348388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Theranostic nanomedicine.
    Lammers T; Aime S; Hennink WE; Storm G; Kiessling F
    Acc Chem Res; 2011 Oct; 44(10):1029-38. PubMed ID: 21545096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
    Hock SC; Ying YM; Wah CL
    PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing the challenges to increase the efficiency of translating nanomedicine formulations to patients.
    Bhattacharjee S; Brayden DJ
    Expert Opin Drug Discov; 2021 Mar; 16(3):235-254. PubMed ID: 33108229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
    Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
    Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicines: Redefining traditional medicine.
    Lu W; Yao J; Zhu X; Qi Y
    Biomed Pharmacother; 2021 Feb; 134():111103. PubMed ID: 33338747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine.
    Cai R; Chen C
    Adv Mater; 2019 Nov; 31(45):e1805740. PubMed ID: 30589115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.